# OnCo record nct03228667 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03228667/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03228667", "NCT03228667" ;
  schema:name "QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors"@en ;
  schema:alternateName "QUILT-3"@en ;
  schema:description "A phase 2 trial of Nogapendekin alfa inbakicept, Pembrolizumab, Nivolumab in non-small-cell lung cancer and small-cell lung cancer, run by ImmunityBio, Inc., active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct03228667/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03228667> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2018-12-11" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/merkel-cell-carcinoma/>, <https://onco.cc/cancers/melanoma/> ;
  onco:drugs <https://onco.cc/drugs/nogapendekin-alfa/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/avelumab/>, <https://onco.cc/drugs/durvalumab/> ;
  onco:companies <https://onco.cc/companies/immunitybio/> .